After Myriad: Genetic Testing in the Wake of Recent Supreme Court Decisions about Gene Patents
Open Access
- 11 September 2014
- journal article
- research article
- Published by Springer Nature in Current Genetic Medicine Reports
- Vol. 2 (4) , 223-241
Abstract
Genetic testing is becoming more common and more powerful by the day. The costs of the underlying DNA sequencing technology are plummeting, making it likely that tests based on it will become even more pervasive. The use of tests to determine DNA sequence to help make clinical decisions is here to stay. DNA sequencing is also finding new uses in forensics, determination of ancestry, understanding the history and genetic lineages of human populations and many other applications.Keywords
This publication has 11 references indexed in Scilit:
- Gene Jockeys2014
- Constructing narratives of heroism and villainy: case study of Myriad's BRACAnalysis® compared to Genentech's Herceptin®Genome Medicine, 2013
- Myriad Genetics: In the eye of the policy stormGenetics in Medicine, 2010
- Gene patents and licensing: Case studies prepared for the Secretary's Advisory Committee on Genetics, Health, and SocietyGenetics in Medicine, 2010
- Impact of gene patents and licensing practices on access to genetic testing and carrier screening for Tay-Sachs and Canavan diseaseGenetics in Medicine, 2010
- Legal uncertainty in the area of genetic diagnostic testingNature Biotechnology, 2009
- Myriad and the mass media: the covering of a gene patent controversyGenetics in Medicine, 2007
- Evidence and anecdotes: an analysis of human gene patenting controversiesNature Biotechnology, 2006
- Effects of Patents and Licenses on the Provision of Clinical Genetic Testing ServicesThe Journal of Molecular Diagnostics, 2003
- Families Sue Hospital, Scientist for Control of Canavan GeneScience, 2000